We aimed to investigate a possible role of endocrine disruptors phthalates, di-2-ethylhexyl phthalate (DEHP) and mono (2-ethylhexyl) phthalate (MEHP), in polycystic ovary syndrome (PCOS) aetiopathogenesis. We also wished to evaluate the relationship between phthalates and metabolic disturbances in adolescents with PCOS. A total of 124 adolescents (63 PCOS, 61 controls, mean age: 15.2±1.5 age range: 13-19 years) were included in the study. Serum MEHP and DEHP levels were determined with HPLC method. Insulin resistance was evaluated using HOMA-IR, QUICK-I, fasting glucose /insulin ratio, Matsuda index, and total insulin levels during OGTT. Participants were further subdivided into lean and obese subgroups according to body mass index. Serum DEHP and MEHP levels were not significantly different between PCOS and control groups. The mean (95% CI) values of DEHP and MEHP were 2.62 (2.50-2.75) µg/ml vs 2.71 (2.52-2.90) µg/ml and 0.23 (0.19-0.29) µg/ml vs 0.36 (0.18-0.54) µg/ml in PCOS and the control groups respectively, p>0.05). The correlation analysis adjusted for BMI revealed that both phthalates significantly correlated with insulin resistance indices and serum triglycerides in adolescents with PCOS. Serum DEHP and MEHP concentrations were not different between adolescents with or without PCOS. However, these phthalates are associated with metabolic disturbances such as dyslipidemia and insulin resistance, independently of obesity, in girls with PCOS.
21 November 2023 in Journal of Clinical Research in Pediatric Endocrinology
Neonatal diabetes and congenital hypothyroidism syndrome (NDH) is a rare condition caused by homozygous or compound heterozygous mutations in the GLIS3 gene. Small for gestational age (SGA), congenital glaucoma, polycystic kidney disease, cholestatic hepatic fibrosis, pancreatic exocrine insufficiency, developmental delay, dysmorphic facial features, sensorineural deafness, osteopenia, and skeletal anomalies are other accompanying phenotypic features in 22 cases described so far. We present a male case with neonatal diabetes, congenital hypothyroidism, congenital glaucoma, developmental delay, and facial dysmorphic features. During the patient's 17-year follow-up, no signs of exocrine pancreatic insufficiency, liver and kidney diseases, deafness, osteopenia, and bone fracture were observed. A homozygous exon 10-11 deletion was detected in the GLIS3 gene. We report one of the oldest surviving GLIS3 mutation case with main findings of neonatal diabetes and congenital hypothyroidism syndrome to contribute to the characterization of the genotypic and phenotypic spectra of the syndrome.
20 November 2009 in European Journal of Pediatrics
Objective: No large study has been conducted to date to compare the effectiveness of prednisolone, alendronate and pamidronate as first-line treatment in children with hypercalcemia due to vitamin D intoxication. The aim was to perform a multicenter, retrospective study assessing clinical characteristics and treatment results. Methods: A standard questionnaire was uploaded to an online national database system to collect data on children with hypercalcemia (serum calcium level > 10.5 mg/dL) due to vitamin D intoxication [serum 25-hydroxyvitamin D (25(OH)D) level > 150 ng/mL] who were treated in pediatric endocrinology clinics. Results: Seventy-four children [median (range) age 1.06 (0.65-1.60) years, 45 males (61 %) from II centers] were included. High-dose vitamin D intake was evident in 77% of the cases. At diagnosis, serum calcium, phosphorus, alkaline phosphatase, 25(OH)D and parathyroid hormone concentrations were 15 +/- 3.2 mg/dl., 5.2 +/- 1.2 mg/dL, 268 +/- 132 IU/L, 322 (236-454) ng/ml, and 5.5 (3-10.5) pg/mL, respectively. Calcium levels showed moderate correlation with 25(OH)D levels (r(s) = 0.402, p <0.001). Patients were designated into five groups according to the initial specific treatment regimens (hydration-only, prednisolone, alendronate, pamidronate, and combination). Need for another type of specific drug treatment was higher in children who initially received prednisolone (p <0.000). Recurrence rate of hypercalcemia was significantly lower in children who were treated with pamidronate (p=0.02). Conclusion: Prednisolone is less effective in the treatment of children with severe hypercalcaemia secondary to vitamin D intoxication and timely implementation of other treatment regimens should be considered.
19 March 2018 in Journal of Clinical Research in Pediatric Endocrinology
Rapid-onset obesity with hypoventilation, hypothalamic dysfunction and autonomic dysregulation (ROHHAD) syndrome is a rare disease that is difficult to diagnosis and distinguish from genetic obesity syndromes. The underlying causes of the disease have not been fully explained. Hypothalamic dysfunction causes endocrine problems, respiratory dysfunction and autonomic alterations. Currently there are around 80 reported patients although this is likely due to underdiagnosis due to lack of recognition. We present two female patients suspected of ROHHAD due to weight gain starting in early childhood. Clinical and biochemical findings such as respiratory and circulatory dysfunction, hypothalamic hypernatremia, central hypothyrodism, hyperprolactinemia and central early puberty in these patients matched the criteria for ROHHAD syndrome. ROHHAD syndrome should be considered in the differential diagnosis of monogenic obesity.
12 October 2016 in Turkish Journal of Biochemistry
Introduction: The aim of this study was to analyze serum ischemia modified albumin (IMA) and plasma CoQ10 levels and to evaluate their correlation with insulin resistance (homeostatic model assessment, HOMA) and lipid profile in obese children with and without metabolic syndrome (MS). Methods: Thirty-one obese with MS, 30 obese without MS and 34 healthy children aged 6–18 years were included in the study. Serum IMA was measured by colorimetric method, plasma CoQ10 levels were measured by HPLC. Serum glucose, total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol and insulin were analyzed. Results: IMA levels were found to be significantly higher (p<0.001) while the CoQ10 levels were significantly lower (p<0.001) in obese children with and without MS compared to controls. IMA and CoQ10 significantly correlated with each other and metabolic parameters. Furthermore, IMA and CoQ10 levels did not significantly differ between obese children with and without MS, while glucose, insulin levels and HOMA were significantly higher (p<0.001) in obese children with MS than obese without MS and controls. Conclusions: Based on the high levels of IMA, low CoQ10 and association with HOMA and lipid profile; we suggest that obese children may have oxidative damage, lipid peroxidation and cardiometabolic risk.